Draig Therapeutics raises $65 million Series B to push depression drug targeting synapse repair
read at Endpoints ↗DealPositive
Draig Therapeutics announced it has closed a $65 million Series B financing round that was oversubscribed.
The capital will be used to advance its neuropsychiatry pipeline, with the lead program focused on a depression candidate that modulates the AMPA receptor to promote synapse rebuilding.
The funding underscores investor confidence in the company’s approach to addressing unmet needs in mental health, and positions Draig to move the candidate further toward clinical development.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Draig nets $65M to advance depression drug aimed at rebuilding synapses”
read at Endpoints ↗83 words · retrieved Jul 14
comments(0)
5-min edit window · permanent after that